name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.-3delA	c.-3delA				28270	N	intergenic		4	5	0						0	T=4	4	T	TA						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
c.A-31T	c.A-31T				26492	M	intergenic		5	5	0						0	T=5	5	T	A						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		5	5	0						0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
c.C-87T	c.C-87T				27807	ORF8	intergenic		4	5	0						0	T=4	4	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
c.G29779T	c.G*4395T				29779	intergenic	3' UTR		5	5	0						0	T=5	5	T	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
c.GCCACGCGGAGTACGATCGAGT29737G	c.*4354_*4374delCCACGCGGAGTACGATCGAGT				29737	intergenic	Stem-loop,3' UTR		5	5	0						0	G=5	5	G	GCCACGCGGAGTACGATCGAGT						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.A2355S	c.G7063T	p.A2355S			7328	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=5	5	T	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.C136_Y144del	c.405_431delTTGTAATGATCCATTTTTGGGTGTTTA	p.C136_Y144del			21966	S	S		4	5	0						0	T=4	4	T	TTTGTAATGATCCATTTTTGGGTGTTTA						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D1849D	c.C5547T	p.D1849D			5812	orf1ab	ORF1ab	SILENT	5	5	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=4	4	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D22Y	c.G64T	p.D22Y			28337	N	N	MISSENSE	5	5	0						0	T=5	5	T	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D3897D	c.C11691T	p.D3897D			11956	orf1ab	ORF1ab	SILENT	5	5	0			nsp7	produced by both pp1a and pp1ab	YP_009725303.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D5437D	c.C16311T	p.D5437D			16575	orf1ab	ORF1ab	SILENT	5	5	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'R190S'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'R190S'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralâ€“nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	10	10	0						0	G=10	10	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9â€“11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationâ€”mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'R190S'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	5	5	0						0	G=5	5	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D936H	c.G2806C	p.D936H			24368	S	S	MISSENSE	5	5	0						0	C=5	5	C	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.D992A	c.A2975C	p.D992A			3240	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4	C=1	1	C	A						False	B.1.640.1	B.1.640.1=False	VUM			22-Nov-2021
p.E378Q	c.G1132C	p.E378Q			29405	N	N	MISSENSE	5	5	0						0	C=5	5	C	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.E452G	c.A1355G	p.E452G			1620	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	G=5	5	G	A						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.E96Q	c.G286C	p.E96Q			21848	S	S	MISSENSE	5	5	0						0	C=5	5	C	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.F490R	c.TT1468_1469CG	p.F490R			23030	S	S		5	5	0						0	CG=5	5	CG	TT	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.F6673F	c.C20019T	p.F6673F			20283	orf1ab	ORF1ab	SILENT	5	5	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	5	5	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.G112G	c.C336T	p.G112G			601	orf1ab	ORF1ab	SILENT	5	5	0			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.I210T	c.T629C	p.I210T			22191	S	S	MISSENSE	4	5	0						0	C=4	4	C	T						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.I82T	c.T245C	p.I82T			26767	M	M	MISSENSE	5	5	0						0	C=5	5	C	T	homoplasy	Shen et al. (2021)	https://doi.org/10.1080/22221751.2021.1922097		This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.K249K	c.A747G	p.K249K			29020	N	N	SILENT	5	5	0						1	G=4	4	G	A						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.L2119F	c.G6357T	p.L2119F			6622	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=5	5	T	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.L730L	c.C2190T	p.L730L			2455	orf1ab	ORF1ab	SILENT	5	5	0			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.L84L	c.C250T	p.L84L			21812	S	S	SILENT	5	5	0						2	T=3	3	T	C						False	B.1.640.1	B.1.640.1=False	VUM			22-Nov-2021
p.N1578N	c.C4734T	p.N1578N			4999	orf1ab	ORF1ab	SILENT	5	5	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=4	4	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N394S	c.A1181G	p.N394S			22743	S	S	MISSENSE	5	5	0						0	G=5	5	G	A						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Î”69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	10	10	0						0	T=10	10	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 Âµg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	5	5	0						0	T=5	5	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.N556K	c.C1668A	p.N556K			23230	S	S	MISSENSE	5	5	0						4	A=1	1	A	C						False	B.1.640.1	B.1.640.1=False	VUM			22-Nov-2021
p.N8N	c.T24C	p.N8N			28297	N	N	SILENT	5	5	0						0	C=5	5	C	T						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P309L	c.C926T	p.P309L			1191	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P368P	c.T1104C	p.P368P			29377	N	N	SILENT	5	5	0						0	C=5	5	C	T						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	5	5	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	5	5	0						0	A=5	5	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.P9L	c.C26T	p.P9L			21588	S	S	MISSENSE	5	5	0						0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.Q272L	c.A815T	p.Q272L			29088	N	N	MISSENSE	5	5	0						4	T=1	1	T	A						False	B.1.640.1	B.1.640.1=False	VUM			22-Nov-2021
p.Q27X	c.C79T	p.Q27X			27972	ORF8	ORF8	NONSENSE	4	5	0						0	T=4	4	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.Q57H	c.G171T	p.Q57H			25563	ORF3a	ORF3a	MISSENSE	5	5	0						0	T=5	5	T	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	4	5	0						0	T=4	4	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	4	5	0						0	T=4	4	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	4	5	0						0	T=4	4	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	4	5	0						0	T=4	4	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R3164H	c.G9491A	p.R3164H			9756	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	A=5	5	A	G						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R346S	c.A1038C	p.R346S			22600	S	S	MISSENSE	5	5	0						0	C=5	5	C	A	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R346S	c.A1038C	p.R346S			22600	S	S	MISSENSE	5	5	0						0	C=5	5	C	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to class 2/3 antibody C603.	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.R346S	c.A1038C	p.R346S			22600	S	S	MISSENSE	5	5	0						0	C=5	5	C	A	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Positive selection (up to 30% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.S3149F	c.C9446T	p.S3149F			9711	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.S4912G	c.A14734G	p.S4912G			14998	orf1ab	ORF1ab	MISSENSE	5	5	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	1	G=4	4	G	A						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.T205I	c.C614T	p.T205I			28887	N	N	MISSENSE	5	5	0						0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.T3255I	c.C9764T	p.T3255I			10029	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.T32I	c.C95T	p.T32I			25487	ORF3a	ORF3a	MISSENSE	5	5	0						0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.T859N	c.C2576A	p.T859N			24138	S	S	MISSENSE	5	5	0						0	A=5	5	A	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.V3524F	c.G10570T	p.V3524F			10835	orf1ab	ORF1ab	MISSENSE	5	5	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	4	T=1	1	T	G						False	B.1.640.1	B.1.640.1=False	VUM			22-Nov-2021
p.V3718A	c.T11153C	p.V3718A			11418	orf1ab	ORF1ab	MISSENSE	5	5	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	C=5	5	C	T						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.V5054V	c.A15162G	p.V5054V			15426	orf1ab	ORF1ab	SILENT	5	5	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	1	G=4	4	G	A						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.Y40Y	c.C120T	p.Y40Y			27513	ORF7a	ORF7a	SILENT	5	5	0						0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.Y449N	c.T1345A	p.Y449N			22907	S	S	MISSENSE	5	5	0						0	A=5	5	A	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.07 fold	False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.Y5535Y	c.C16605T	p.Y5535Y			16869	orf1ab	ORF1ab	SILENT	5	5	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
p.Y717Y	c.C2151T	p.Y717Y			2416	orf1ab	ORF1ab	SILENT	5	5	0			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=5	5	T	C						False	B.1.640.1	B.1.640.1=True	VUM			22-Nov-2021
